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Abstract 
Background: Patients with glucocorticoid-induced osteoporosis (GIOP) are at very high risk of fracture, and patients 
with severe GIOP often experience fractures during treatment with bisphosphonates. Teriparatide (TPTD) is the only 
currently available anabolic agent expected to be effective for GIOP. Once-weekly TPTD decreased bone resorption 
marker with primary osteoporosis different from daily TPTD, but it has not yet been tested with GIOP.
Objectives: To evaluate the efficacy of once-weekly TPTD for patients with GIOP and inadequate response to 
bisphosphonates.
Methods: Patients with GIOP and collagen diseases treated with prednisolone for at least 6 months with inadequate 
responses to bisphosphonates were administered once-weekly TPTD. Bone density of the lumbar spine and femoral 
neck, measured as percent young adult mean (YAM); serum concentrations of cross-linked N-terminal telopeptides of 
type I collagen (NTx), bone alkaline phosphatase (BAP), and calcium; and FRAX were measured at baseline and 6, 12 
and 18 months after starting TPTD.
Results: Of the 12 GIOP patients with collagen diseases enrolled, nine (seven females, two males; mean age 
57.4 ± 11.1 years) completed treatment, including six with systemic lupus erythematosus, two with rheumatoid 
arthritis, and one with adult onset still disease. Only one new fracture event, a lumbar compression fracture, occurred 
during the study period, although seven patients experienced eight fracture events within 18 months before starting 
TPTD (p = 0.04). Lumbar spine YAM significantly improved at 18 months (p = 0.04), whereas femoral neck YAM did not 
(p = 0.477). Serum NTx, BAP, Ca, and FRAX were not significantly affected by TPTD treatment.
Conclusions: Once-weekly TPTD reduces fracture events and increases bone density of the lumbar spine of GIOP 
patients with inadequate response to bisphosphonates.
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Background
Glucocorticoids are widely utilized to treat many col-
lagen diseases. Due to their extensive use, glucocorti-
coid therapy is the most common cause of secondary 
and drug-induced osteoporosis. The pathophysiology of 
glucocorticoid-induced osteoporosis (GIOP) is multi-
factorial, with osteoblastic dysfunction being an impor-
tant aspect in the mechanism of glucocorticoid effects 
(Dalle Carbonare et  al. 2005; (Patschan et  al. 2001). 
Moderate doses of oral glucocorticoids inhibit synthe-
sis of bone collagen by osteoblasts and the conversion 
of precursor cells into functioning osteoblasts (Patschan 
et  al. 2001). Moreover, oral glucocorticoids were shown 
to have direct pro-apoptotic effects on osteoblasts in a 
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mouse model (O’Brien et al. 2004). Glucocorticoids also 
modify the synthesis, release, and receptor binding of 
locally produced growth factors (Canalis 1996). These 
adverse effects of glucocorticoids on bone formation 
reduce the total amount of bone (Dalle Carbonare et al. 
2005). Agents that promote bone formation are needed 
for patients with GIOP.
Teriparatide (TPTD), a human parathyroid hormone 
analog, is the only currently available anabolic agent 
that stimulates osteoblast activity (Borggrefe et al. 2010); 
(Sibai et  al. 2011). TPTD has been shown to increase 
bone mass, improve bone quality, and reduce the risk 
of fracture in patients with severe osteoporosis (Toulis 
et al. 2011). Daily administration of recombinant TPTD 
has been shown to be effective in the treatment of non-
union fractures (Oteo-Alvaro and Moreno 2010); (Lee 
et  al. 2012). Daily TPTD increased bone mineral den-
sity more than alendronate in GIOP (Saag et  al. 2007). 
Although assays of markers of bone metabolism showed 
that daily TPTD increased markers of bone formation 
and bone resorption, the balance favored bone formation 
(Miyauchi et al. 2010).
Once-weekly chemically synthesized TPTD has been 
shown to have rapid and powerful anti-fracture activity 
(Nakamura et  al. 2012); (Nakano et  al. 2014), increas-
ing the bone mineral density (BMD) of cancellous but 
not cortical bone (Sone et al. 1995). Once-weekly TPTD 
significantly reduced NTx levels from baseline by 12.2 % 
at 48 weeks and thereafter (Nakamura et al. 2012). This 
reduction of bone resorption activity is the unique fea-
ture of once-weekly TPTD although daily TPTD increase 
bone resorption marker (McClung et al. 2005). Even after 
treatment with bisphosphonates, once-weekly TPTD 
injections reduced the risk of vertebral fracture and 
increased BMD with primary osteoporosis subjects. Glu-
cocorticoid promotes bone resorption activity in addition 
to the reduction of bone formation. Therefore, these find-
ings suggested that once-weekly TPTD may be effective 
in patients with GIOP. This pilot study assessed the effi-
cacy of once-weekly TPTD for GIOP patients with inad-
equate response to bisphosphonates.
Methods
Study design
The study cohort consisted of patients at our institution 
with GIOP and collagen diseases, who showed inad-
equate responses to bisphosphonates. Patients received 
subcutaneous injections of 56.5 μg of TPTD once-weekly 
for 18  months. During the study, all the patient con-
comitantly received vitamin D. Markers of osteoporosis 
were assessed at baseline and after 6, 12 and 18 months 
of treatment. The study protocol was approved by the 
responsible institutional review boards at our hospital 
(RBMR-C-1154-3), was conducted in accordance with 
the ethical standards of the Declaration of Helsinki, and 
was consistent with good clinical practice.
Participants
Osteoporosis was diagnosed according to the guidelines 
on the management and treatment of GIOP of the Japa-
nese Society for Bone and Mineral Research (Nawata 
et al. 2005), i.e., with BMD at the lumbar spine or femoral 
neck <80 % of the young adult mean (YAM) in the Japa-
nese population. Moreover, all patients were treated with 
corticosteroids for at least 6  months, but experienced 
new fractures or decreased BMD despite treatment 
with bisphosphonates, after which patients were started 
on once-weekly TPTD instead of bisphosphonates. All 
patients provided written informed consent.
Efficacy measures
Bone mineral density of the lumbar spine and hip 
was measured in nine and six subjects, respectively, 
using dual-energy x-ray absorptiometry (Discov-
ery Wi; Hologic, Bedford, MA) at baseline and at 6, 12 
and 18  months. BMD and YAM were determined, and 
changes from baseline were calculated.
Serum samples were obtained under nonfasting condi-
tions before injection of TPTD. All measurements were 
performed centrally in a single batch at our hospital and 
a validated institution (SRL, Tokyo, Japan). Serum con-
centrations of the bone formation marker bone alkaline 
phosphatase (BAP); the bone resorption marker cross-
linked N-telopeptide of type I collagen (NTx), and cal-
cium were measured at baseline and after 6, 12 and 
18  months. Serum BAP was measured using a chemi-
luminescent enzyme immunoassay and serum NTx by 
enzyme-linked immunoassay.
Fractures
Morphometric fractures were assessed in frontal and lat-
eral spine, and hip radiographs were obtained at baseline 
and after 6, 12 and 18  months. Clinical fractures were 
defined as those confirmed on radiographs, accompanied 
by clinically evident symptoms such as pain in the ver-
tebral or non-vertebral region. Both morphometric and 
clinical fractures were counted as fracture events.
The fracture risk assessment tool (FRAX) is a scien-
tifically validated risk assessment tool endorsed by the 
World Health Organization that assesses the 10-year 
probability of fracture. Ten-year probabilities of hip 
and major osteoporotic fractures were calculated using 
the official calculation web tool of the World Health 
Organization.
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Adverse events
Patients underwent regular physical examinations, hema-
tological monitoring, measurements of blood chemistry, 
and urinary examinations. All adverse events that led to 
withdrawal from the study were recorded.
Statistical analysis
Percent changes from baseline in BMD, YAM, FRAX, 
serum calcium, and bone turnover markers at each time 
point were compared with baseline measurements using 
ANOVA and Wilcoxon matched-pairs single rank tests. 
All statistical analysis were performed using GraphPad 
Prism statistical software (Version 5, GraphPad Software, 
San Diego, CA, USA), and all had a two-sided signifi-
cance level of 0.05.
Results
Subjects
Twelve GIOP patients with collagen disease were enrolled 
into this study, including six with systemic lupus erythe-
matosus (SLE), three with rheumatoid arthritis (RA), one 
with mixed connective tissue disease, one with systemic 
sclerosis, and one with adult onset still disease (AOSD). 
One patient stopped TPTD after the first dose due to 
nausea, and two discontinued within 6  months because 
of onset of another disease unassociated with TPTD, 
including one patient with malignant lymphoma and the 
other with purulent arthritis of the hip and abscess in the 
iliopsoas muscle. The remaining nine patients completed 
this study; their baseline demographic and clinical char-
acteristics, including concentrations of bone metabolic 
markers, are shown in Table 1. The nine patients, of mean 
age 57.4  years, included six with SLE (five females and 
one male), two with RA (one female and one male), and 
one female with AOSD. At baseline, their mean BMD was 
0.74 at the lumbar spine and 0.62 at the femoral neck, and 
their mean YAM at these two sites was 73.1 and 72.0 %, 
respectively. Prior to starting TPTD treatment, seven of 
the nine subjects experienced vertebral or non-vertebral 
fractures, including seven who experienced fractures 
within 18  months before this study, regardless of their 
BMD. In remaining two patients, BMD decreased in spite 
of bisphosphonate treatment. Mean BAP at baseline was 
10.8  µg/L and mean serum NTx was 13.8  nmol BCE/L. 
All patients received the administration of vitamin D. 
Disease activities including DAS28-CRP and SLEDAI 
were not changed during study period.
Bone mineral density
At 18 months, YAM increased 8.27 % at the lumbar spine 
(p = 0.041, ANOVA; p = 0.019, Wilcoxon matched-pairs 
single rank test), but decreased −2.85  % at the femoral 
neck (p = 0.477, ANOVA) (Fig. 1a, b). BMD at these sites, 
however, did not change significantly during TPTD treat-
ment (Fig.  1c, d), but tended to increase at the lumbar 
spine.
Bone turnover markers
Serum BAP (Fig. 2a) and NTx (Fig. 2b) tended to increase 
during TPTD treatment, but not significantly. Serum cal-
cium concentration was unchanged (Fig. 3).
Fractures
FRAX for hip and major fractures remained constant 
during TPTD administration (Fig.  4a, b). The num-
ber of fracture events and patients with new fractures 
18  months before or after TPTD treatment in Table  2. 
During the 18  months before TPTD treatment, seven 
patients experienced eight fracture events. During the 
18 months of TPTD treatment, only one patient, a female 
with SLE, experienced a new radiographic vertebral 
fracture or investigator-assessed non-vertebral fracture 
(p = 0.04). This patient had three fracture events within 
18 months before the start of the study, and showed a sig-
nificant reduction from baseline in BAP concentration. 
Safety
Of the 12 patients enrolled, nine patients completed this 
study. One patient discontinued TPTD due to nausea 
Table 1 Baseline characteristics of  patients who received 
once-weekly teriparatide injections for 18 months
Data are shown as mean ± SD
SLE systemic lupus erythematosus, RA rheumatoid arthritis, AOSD adult onset 
still disease, PSL prednisolone, YAM young adult mean, BMD bone mineral 
density, Ca calcium, BAP bone alkaline phosphatase, NTx type 1 collagen cross-
linked N-telopeptide
Sex (n) Female: 7, male: 2
Age (year) 57.4 ± 11.1
Disease (n) SLE 6, RA 2, AOSD 1
PSL dose at baseline (mg/day) 10 ± 6.6
Fracture events within 18 months before TPTD 
treatment (n)
8 events of 7 patients
Lumbar spine YAM (%) 73.1 ± 11.9
Total hip YAM (%) 72 ± 10.0
Lumbar spine BMD 0.74 ± 0.11
Total hip BMD 0.62 ± 0.11
Ca (mg/dl) 9.1 ± 0.5
BAP (µg/L)
Reference value; male 3.7–20.9, Premenopau-
sal female 2.9–14.5, Postmenopausal female 
3.8–22.6
10.8 ± 4.6
Serum NTx (nmol BCE/L)
Reference value; Male 9.5–17.7, Premenopau-
sal female 7.5–16.5, Postmenopausal female 
10.7–24.0
13.8 ± 4.4
FRAX: major fracture (%) 20.5 ± 16.7
FRAX: hip fracture (%) 8.8 ± 11.4
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at first administration. Through 18 months, none of the 
patients who completed this study experienced any sig-
nificant adverse events.
Discussion
This study indicated that once-weekly TPTD was effec-
tive for subjects with GIOP who were non-responsive to 
Fig. 1 Mean percent changes in bone density from baseline during TPTD treatment. Changes over time in a Lumbar spine YAM; b Femoral neck 
YAM; c Lumbar spine BMD; d Femoral neck BMD. Results were compared using †ANOVA and ‡Wilcoxon matched-pairs single rank test; *p < 0.05; 
bars indicate 95 % CI
Fig. 2 Mean percent changes in bone turnover markers from baseline during TPTD treatment. Percent changes over time in a mean BAP; and b 
mean serum NTx. Differences were compared using ANOVA; bars indicate 95 % CI. BAP was representative of bone formation marker, and NTx was 
for bone resorption marker
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bisphosphonate therapy. TPTD reduced fracture events 
and increased BMD at the lumbar spine. Moreover, it 
was indicated the new sights of bone metabolism marker 
change in GIOP treated with once-weekly TPTD. The 
mean serum concentration of NTx, a bone resorption 
marker, increased during treatment, although former 
study showed NTx levels decreased under onece-weekly 
TPTD treatment of primary osteoporosis (Nakamura 
et al. 2012).
Glucocorticoid induces osteoporosis mainly by sup-
pressing osteoblast-mediated osteogenesis. Glucocor-
ticoids can suppress osteoblastic differentiation and 
activity, both of which many be overcome by PTH 
and bisphosphonates (Hayashi et  al. 2009). An in  vitro 
study showed that low-dose PTH reversed gluco-
corticoid-inhibited alkaline phosphatase activity (Iu 
et  al. 2005). Intermittent PTH was found to prevent 
glucocorticoid-induced osteoblast and osteocyte apop-
tosis and preserve the rate of bone formation, BMD, and 
strength (Weinstein et al. 2010). These findings indicate 
that TPTD is suitable for treatment of GIOP.
TPTD is a unique anabolic agent that accelerates bone 
formation. Daily TPTD has been shown to reduce bone 
fractures, especially in the vertebrae, increasing BMD at 
the lumbar spine (Reeve et al. 1976), and reducing non-
union fractures (Aspenberg and Johansson 2010). Spine 
and hip BMD were increased more by daily TPTD than 
by alendronate in patients with GIOP (Saag et al. 2009). 
Additionally, daily TPTD for 18 months was superior to 
risedronate in improving lumbar spine BMD, as meas-
ured by quantitative computed tomography, in males 
with GIOP (Glüer et al. 2013).
Recently, once-weekly TPTD has been available for 
severe osteoporosis in addition to daily TPTD. One of 
the most important difference between once-weekly and 
daily TPTD is change in bone resorption marker. Once-
weekly TPTD reduces bone resorption markers in addi-
tion to increasing bone formation markers, as compared 
to daily TPTD that increase bone resorption markers 
(Miyauchi et al. 2010). Glucocorticoid also promote bone 
resorption. Therefore, once-weekly TPTD is thought to 
be more suitable for GIOP treatment than daily TPTD.
The efficacy of once-weekly TPTD had not been 
tested for GIOP. A double-blinded randomized clini-
cal trial for primary osteoporosis patients confirmed 
that once-weekly TPTD increased lumbar BMD 
dose-dependently after 24 and 48  weeks, although the 
radiogrammetric density of cortical bone did not dif-
fer significantly (Fujita et  al. 1999). This study found 
that once-weekly TPTD for 18  months significantly 
increased YAM of the lumbar spine, as well as reduc-
ing fracture events. Prior fracture is an important risk 
Fig. 3 Mean serum calcium concentration during TPTD treatment. 
Mean serum calcium concentrations over time. Differences were 
compared using ANOVA; bars indicate 95 % CI
Fig. 4 Mean FRAX score during TPTD treatment. Changes over time in FRAX scores. a Major fractures; and b Hip fractures. Differences were com-
pared using ANOVA; bars indicate 95 % CI
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factor for future fractures (Klotzbuecher et  al. 2000). 
In our study, TPTD prevented the fracture events in 
the six patients who had one fracture event during 
18 months before TPTD. A female SLE patient, who had 
two fractures within 18  months before starting TPTD, 
suffered only one fracture during TPTD treatment. Fur-
thermore she was treated with denosumab after once-
weekly TPTD, she did not fracture under denosumab. 
Swithing from TPTD to denosumab improved bone 
mineral density effectively in postmenopousal osteopo-
rosis (Leder et  al. 2015). Preseding once-weekly TPTD 
might be beneficial for prevention of fracture. Addition-
ally, YAM was improved at 18 months in our study, but 
it was not increased at 12 months. We assumed the rea-
son that patients enrolled in this study were very severe 
with osteoporosis. This fact showed that we needed 
TPTD treatment for 18  months in order to improve 
GIOP. Taken together, 18 months of once-weekly TPTD 
reduced fractures in GIOP patients.
Our study also indicated the new findings of bone 
turnover makers. Assessments of bone turnover mak-
ers during once-weekly TPTD administration found that 
the bone formation markers BAP and osteocalcin were 
increased, while the bone resorption marker urinary 
deoxypiridinoline was decreased (Sugimoto et  al. 2014), 
as was urinary NTx (Nakamura et al. 2012). Thus, weekly 
TPTD not only enhances bone formation but suppresses 
bone resorption. Our study found, however, that the 
increase in BAP was smaller than previously reported 
and that serum NTx increased. Although daily TPTD 
tended to increase serum calcium level, weekly TPTD 
maintained calcium concentration (Sone et al. 1995). Our 
study found that serum calcium did not change during 
18  months of treatment with once-weekly TPTD. This 
study, however, included only patients with severe GIOP 
who were unresponsive to bisphosphonates, which may 
have reduced the impact of TPTD on bone turnover 
markers.
Moreover, lower frequency of administration decreases 
the burden on patients and enhance the convenience. 
Thus, once-weekly administration has the advantage 
even if its beneficial effect is equivalent to daily TPTD.
This study had several limitations, including the very 
small size of the study population and the evaluation 
of only two bone turnover markers, BAP and NTx. 
Other markers of bone turnover, including osteocalcin, 
P1NP, and deoxypiridinoline, were not measured. Third, 
patients did not receive supplementary calcium and mag-
nesium as basic treatment for osteoporosis.
In conclusion, this study is the first to our knowledge to 
show that once-weekly TPTD reduced fracture events and 
increased the YAM of the lumbar spine in GIOP patients 
with inadequate response to bisphosphonates. Once-
weekly TPTD was well tolerated and compliance was 
good. Although these findings suggest that TPTD may be 
safe and effective for GIOP patients with collagen diseases, 
further studies in larger patient populations are required 
to determine the efficacy of once-weekly TPTD for GIOP.
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